Teva Pharmaceutical Industries (TEVA) Cash & Current Investments (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash & Current Investments for 18 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 69.13% year-over-year to $3.7 billion; the trailing twelve-month figure through Jun 2026 stood at $3.7 billion (up 69.13% YoY), and the FY2025 full-year result was $3.6 billion, up 7.76% from the prior year.
• Cash & Current Investments eased to $3.7 billion in Q2 2026 per TEVA's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $3.7 billion in Q1 2026 and bottomed at $1.7 billion in Q1 2025.
• Historically, Cash & Current Investments has averaged $2.7 billion across 5 years, with a median of $2.5 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments sank 43.26% in 2025, then surged 120.45% in 2026.
• Over 5 years, Cash & Current Investments stood at $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then climbed by 2.29% to $3.3 billion in 2024, then advanced by 7.76% to $3.6 billion in 2025, then rose by 2.78% to $3.7 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.7 billion, $3.7 billion, and $3.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.